NovaDel’s USPTO Allowance Notice (AMEX:NVD)
NovaDel Pharma Inc. (AMEX:NVD) announced that they have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715 entitled “Buccal, Polar and Non-Polar Spray containing Zolpidem” that covers a method of treating insomnia by administering zolpidem to human beings utilizing NovaMist Oral Spray spray technology. NovaDel’s oral spray technology is focused for unmet medical needs for a broad array of existing and future pharmaceutical products. The Company’s most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system.
NovaDel Pharma is a leading specialty pharmaceutical company that is into the development of oral spray formulations for a broad range of marketed drugs. The Company offers conventional oral dosage forms that has the potential for faster absorption of drugs into the bloodstream that leads to quick therapeutic effects and reduces first pass liver metabolism that can happen in low doses. Additionally, oral sprays eliminate the use of water or the need to swallow medicines that may prove convenient to the patients. Zolpimist is indicated for the short-term treatment of insomnia characterized by difficulties and problems with sleep initiation.
NovaDel Pharma’s Zolpimist Oral Spray has already been approved by the Food and Drug Administration for the short term treatment of insomnia characterized by difficulties with sleep initiation. This is NovaDel’s second product that has been approved by the FDA that uses NovaDel’s proprietary NovaMist oral spray technology. NovaDel maintains an exclusive worldwide portfolio of intellectual property rights for select compounds using is pioneering oral spray delivery system. Patients who are taking Zolpimist should immediately prepare for bedtime after they take the oral spray and avoid activities like driving or operating dangerous appliances that can cause damage.
